In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci-Reference-Cited by-同舟云学术

In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci

Published:2017-10 Issue:2 Volume:89 Page:168-171
ISSN:0732-8893
Container-title:Diagnostic Microbiology and Infectious Disease
language:en
Short-container-title:Diagnostic Microbiology and Infectious Disease

Author:

Arhin Francis F.,Seguin David Lalonde,Belley Adam,Moeck Gregory

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference20 articles.

1. Agar dilution minimum inhibitory concentrations (MICs) underrepresent oritavancin in vitro activity against staphylococci and enterococci;Arhin;J Glob Antimicrob Res,2017

2. Assessment of the potential for oritavancin MIC changes among Staphylococcus aureus nasal carriage isolates following systemic oritavancin treatment in a phase 2 study in patients with acute bacterial skin and skin-structure infections;Arhin;J Glob Antimicrob Resist,2017

3. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing;Arhin;Antimicrob Agents Chemother,2008

4. Antibiotic resistance in Enterococcus faecium clinical isolates;Cattoir;Expert Rev Anti Infect Ther,2014

5. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. Document M7-A10;Clinical and Laboratory Standards Institute,2015

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glycopeptides: Insights Towards Resistance, Clinical Pharmacokinetics and Pharmacodynamics;Indian Journal of Microbiology;2024-04-27

2. Clinically Approved Antibiotics from 2010 to 2022;CHIMIA;2023-04-26

3. Antibiotic potentiators to combat resistance in methicillin-resistant Staphylococcus aureus (MRSA): A mini review;PROCEEDINGS OF THE 9TH INTERNATIONAL SYMPOSIUM ON INNOVATIVE BIOPRODUCTION INDONESIA ON BIOTECHNOLOGY AND BIOENGINEERING 2022: Strengthening Bioeconomy through Applied Biotechnology, Bioengineering, and Biodiversity;2023

4. New Glycopeptides: Telavancin, Dalbavancin, and Oritavancin;New Antimicrobials: For the Present and the Future;2023

5. Recent Advances in the Development of Semisynthetic Glycopeptide Antibiotics: 2014-2022;ACS INFECT DIS;2022